Drugs for the etiologic treatment of Chagas disease: Myths and Truths

Cynthia V Rivero, Patricia Silvia Romano


Chagas disease is a life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. One of the characteristics of chronic chagasic infection is the parasitic persistence in cardiac and smooth muscle tissues.  For this reason etiologic treatment of Chagas disease in all phases of infection is highly recommended. Despite the high number of trypanocidal drugs that have been discovered in the last years, only two compounds, Benznidazole and Nifurtimox remain as the unique drugs approved for Chagas treatment. Far from ideal, these drugs display low sensitivity and specificity resulting in limited applications, mainly in the onset of the acute phase. Thus there is an urgent need to validate new anti- T. cruzi drugs that can be applied even in the cases of chronic patients, those who today have no safe and effective treatment available. This paper reviews the most important compounds that have been tested in clinical trials and the results obtained to date.




Chagas disease, treatments for chronic phase, Benznidazole, Posaconazole, Cruzipain inhibitors.

Full Text:



World Health Organization. Fact sheet 340: Chagas disease (American Trypanosomiasis). http://www.who.int/mediacentre/factsheets/fs340/en/ (Accessed May 4, 2015).

Bern C. Chagas’Disease. N Engl J Med 2015; 373: 456-66.

Coura, J. R.; Dias, J. C., Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 2009, 104 Suppl 1, 31-40.

Guía para el equipo de salud Nro. 7ISSN 1852-1819 Dirección de Epidemiología - Ministerio de Salud de la Nación Av. 9 de Julio 1925 (C1073ABA), Cdad. Autónoma de Bs. As., República ArgentinaTeléfono: (54-11) 4379-9000 / Web: www.msal.gov.ar Impresión: Agosto/2010.

Viotti R., Alarcón de Noya B., Araujo-Jorge T, Grijalva M. J., Guhl F., López M. C., Ramsey J. M., Ribeiro I., Schijman A. G., Sosa-Estani S., Torrico F., Gascon I., Latin American Network for Chagas Disease, NHEPACHA; Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease. Antimicrobial Agents and Chemotherapy; 2014, 58 (2), 635–639.

Higuchi ML, Benvenuti LA, Reis MM, Metzger M. 2003. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc. Res. 60:96 –107. http://dx.doi.org/10.1016/S0008-6363(03)00361-4.

Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. 2007. Pathogenesis of chronic Chagas heart disease. Circulation 115:1109 –1123. http: //dx.doi.org/10.1161/CIRCULATIONAHA.106.624296.

Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas’ disease. J. Infect. Dis. 1999, 180: 480 –486. http://dx.doi.org/10.1086/314889.

Maya, J. D.; Cassels, B. K.; Iturriaga-Vasquez, P.; Ferreira, J.; Faundez, M.; Galanti, N.; Ferreira, A.; Morello, A., Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 2007, 146 (4), 601-20.

Urbina, J. A.; Docampo, R., Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003, 19 (11), 495-501.

Hall, B. S.; Bot, C.; Wilkinson, S. R., Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011, 286 (15), 13088-95.

Boiani, M.; Piacenza, L.; Hernandez, P.; Boiani, L.; Cerecetto, H.; Gonzalez, M.; Denicola, A., Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem Pharmacol 2010, 79 (12), 1736-45.

Murcia, L.; Carrilero, B.; Saura, D.; Iborra, M. A.; Segovia, M., [Diagnosis and treatment of Chagas disease]. Enferm Infecc Microbiol Clin 2013, 31 Suppl 1, 26-34.

Rassi, A., Jr.; Rassi, A.; Marin-Neto, J. A., Chagas disease. Lancet 2010, 375 (9723), 1388-402.

Mecca, M. M.; Bartel, L. C.; Castro, C. R.; Castro, J. A., Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects. Mem Inst Oswaldo Cruz 2008, 103 (6), 549-53.

Bern, C.; Montgomery, S. P.; Herwaldt, B. L.; Rassi, A., Jr.; Marin-Neto, J. A.; Dantas, R. O.; Maguire, J. H.; Acquatella, H.; Morillo, C.; Kirchhoff, L. V.; Gilman, R. H.; Reyes, P. A.; Salvatella, R.; Moore, A. C., Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007, 298 (18), 2171-81.

Rodriques Coura, J.; de Castro, S. L., A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002, 97 (1), 3-24.

Riarte A.; Velázquez E.; Prado N.; Schijman A. G. Ramírez J.C.; De Rissio A. M.; Hernández Y.; Esteva M.; Luna C.; Sinagra A.; Ruiz A. M. ESTUDIO TRAENA: Evaluación de Potenciales biomarcadores de eficacia terapéutica Informativo N°2. Plataforma de Información clínica en Enfermedad de Chagas. Río de Janeiro, setiembre, 2012.

Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S; BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008, 156(1):37-43. doi: 10.1016/j.ahj.2008.04.001.

Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015, 73(14):1295-306. doi: 10.1056/NEJMoa1507574. Epub 2015 Sep 1.

Bustamante, J. M.; Tarleton, R. L., Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol 2014, 7 (3), 317-25.

Roberts, C. W.; McLeod, R.; Rice, D. W.; Ginger, M.; Chance, M. L.; Goad, L. J., Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003, 126 (2), 129-42.

Lepesheva, G. I.; Villalta, F.; Waterman, M. R., Targeting Trypanosoma cruzi sterol 14alpha-demethylase (CYP51). Adv Parasitol 2011, 75, 65-87.

Urbina, J. A., Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009, 104 Suppl 1, 311-8.

Molina, I.; Gomez i Prat, J.; Salvador, F.; Trevino, B.; Sulleiro, E.; Serre, N.; Pou, D.; Roure, S.; Cabezos, J.; Valerio, L.; Blanco-Grau, A.; Sanchez-Montalva, A.; Vidal, X.; Pahissa, A., Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014, 370 (20), 1899-908.

ClinicalTrials.gov. A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS). http://clinicaltrials.gov/show/NCT01377480 (Accessed June 10, 2015).

Lepesheva, G. I., Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opin Drug Discov 2013, 8 (12), 1479-89.

Drugs for Neglected Diseases initiative. http://www.dndi.org/diseasesprojects/portfolio/azoles-e1224.html (Accessed June 15, 2015).

Buckner, F. S.; Urbina, J. A., Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist 2012, 2, 236-242.

Bahia, M. T.; de Andrade, I. M.; Martins, T. A.; do Nascimento, A. F.; Diniz Lde, F.; Caldas, I. S.; Talvani, A.; Trunz, B. B.; Torreele, E.; Ribeiro, I., Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis 2012, 6 (11), e1870.

Duschak, V. G.; Couto, A. S., Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr Med Chem 2009, 16 (24), 3174-202.

McKerrow, J. H.; Doyle, P. S.; Engel, J. C.; Podust, L. M.; Robertson, S. A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I. D.; Brinen, L. S.; Craik, C. S., Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009, 104 Suppl 1, 263-9.

Bellera, C. L.; Balcazar, D. E.; Vanrell, M. C.; Casassa, A. F.; Palestro, P. H.; Gavernet, L.; Labriola, C. A.; Galvez, J.; Bruno-Blanch, L. E.; Romano, P. S.; Carrillo, C.; Talevi, A., Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem 2015, 93, 338-48.

Sbaraglini ML, Bellera CL, Fraccaroli L, Larocca L, Carrillo C, Talevi A, Alba Soto CD. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents. 2016; 16:30060-7.

Shewan L.G.; Coats A. J. S.; Henein M., Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015; 2:2 DOI: 10.17987/icfj.v2i1.4

DOI: https://doi.org/10.17987/icfj.v7i0.351

Copyright (c) 2016 Patricia Silvia Romano

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.